Greenwich LifeSciences, Inc. Stock Prediction
AI-powered sentiment analysis and prediction trends for GLSI, updated each market day.
GLSI AI Sentiment
AI predicts Greenwich LifeSciences, Inc. stock is likely to decrease over the next 10 market days.
Prediction date: July 2, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About Greenwich LifeSciences, Inc.
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9-amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75% of breast cancers.
Sector
Exchange
Market Cap
$269,051,552
Cap Tier
Employees
13
Headquarters
STAFFORD, TX
Listed Since
Sept. 25, 2020
GLSI Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
GLSI Volatility
Greenwich LifeSciences, Inc. has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
